0750 GMT - Galderma posted strong first-quarter sales figures that increase confidence in its full-year guidance, RBC Capital Markets analysts Alistair Campbell and Charles Weston say in a research note. The Swiss skincare company reiterated its guidance for net sales growth at 10-12% at constant currency. However, it now includes the impact of recently announced U.S. tariffs on its fillers and biostimulators business in the U.S., which accounts for around 9% of total sales, the analysts say. Shares trade 6.2% higher at 85.60 Swiss francs. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 03:51 ET (07:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。